Linklaters LLP (via Public) / Linklaters advises on HUTCHMED's HK$4.17bn HKEX IPO
Linklaters advises on HUTCHMEDâs HK$4.17bn HKEX IPO Linklaters advised the joint sponsors and underwriters on the global offering and listing of HUTCHMED (China) Limited (HUTCHMED) on the main board of the Hong Kong Stock Exchange (Stock Code: 13). HUTCHMED, formerly known as Chi-Med (Hutchison China MediTech), is part of the multinational conglomerate CK Hutchison group. It is a global commercial-stage biopharmaceutical company focused on the discovery, development and commercialisation of targeted therapies and immunotherapies for the treatment of patients with cancer and immunological...